Merck Acquisition Expands Neurodegenerative Research, Treatments

Merck & Co. has purchased Calporta, a developer of neurodegenerative and lysosomal storage disorder treatments, for up to $576 million. Calporta’s preclinical stage TRPML1 agonists—a substance that initiates a physiological response when combined with a receptor—are being studied...